Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: A biomarker of matrix metalloproteinase activity and osteoarthritis in human urine

Analytical Biochemistry

Volumn 369, Issue 1, 2007, Pages 41-53

  Nemirovskiy, Olga ^b   Rodney Mathews, W ^b  

^a Wendy)   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antibody capture; Assay validation; Biomarker; Immunoaffinity; LC MS MS; Matrix metalloproteinase (MMP); Osteoarthritis; Peptide quantification; TIINE

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; COLLAGEN; DEGRADATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PEPTIDES;

ANTIBODY CAPTURE; IMMUNOAFFINITY; LC-MS/MS; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; PEPTIDE QUANTIFICATION; TIINE;

BIOMARKERS;

BIOLOGICAL MARKER; COLLAGEN TYPE 2; MATRIX METALLOPROTEINASE;

ACCURACY; ANTIBODY AFFINITY; ARTICLE; CATALYST; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; LIQUID CHROMATOGRAPHY; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDITY;

EID: 34548169013     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.05.002     Document Type: Article

References (23)

1. Lee J.W., Smith W.C., Nordblom G.D., and Bowsher R.R. Validation of assays for the bioanalysis of novel biomarkers: practical recommendations for clinical investigations of new drug entities. In: Bloom J. (Ed). Biomarkers in Clinical Drug Development (2002), Marcel Dekker, New York 119-148
2. Lee J.W., Viswanath D., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., and Wagner J.A. Fit for purpose method development and validation for successful biomarker measurement. Pharm. Res. 23 (2006) 312-328
3. Lee J.W., Weiner R.S., Sailstad J.M., Bowsher R.R., Knuth D.W., O'Brien P.J., Fourcroy J.L., Dixit R., Pandite L., Petrusko R.G., Soares H.D., Quarmby V., Vesterqvist O.L., Potter D.M., Witliff J.L., Fritche H.A., O'Leary T., Perlee L., Kadam S., and Wagner J.A. Method validation and measurement of biomarkers in non-clinical and clinical samples in drug development: a conference report. Pharm. Res. 22 (2005) 499
4. U.S. Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, FDA, Washington, DC, 2001. (Fed. Reg. 66(100) (2001) 28526).
5. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., and Yacobi A. Bioanalytical method validation: a revisit with a decade of progress. Pharm. Res. 17 (2000) 1551-1557
6. Szekely-Klepser G., Wade K., Woolson D., Brown R., Fountain S., and Kindt E. A validated LC/MS/MS method for the quantification of pyrrole-2,3,5-tricarboxylic acid (PTCA), a eumelanin specific biomarker, in human skin biopsies. J. Chromatogr. B 826 (2005) 31-40
7. Kindt E., Shum Y., Badura L., Snyder P.J., Brant A., Fountain S., and Szekely-Klepser G. Development and validation of an LC/MS/MS procedure for the quantification of endogenous myo -inositol concentrations in rat brain tissue homogenates. Anal. Chem. 76 (2004) 4901
8. Huebner J.L., Otterness I.G., Freund E.M., Caterson B., and Kraus V.B. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum. 41 (1998) 877-890
9. Kraus V.B., Stabler T., Le E.T., Saltarelli M., and Allen N.B. Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis. Arthritis Rheum. 48 (2003) 2942-2948
10. Poole A.R. Biochemical/Immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum. Dis. Clin. N. Am. (2003) 803-818
11. Nemirovskiy O.V., Dufield D.R., Sunyer T., Aggarwal P., Welsch D.J., and Mathews W.R. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for MMP activity: from in vitro to in vivo. Anal. Biochem. 391 (2007) 93-101
12. Harald J., Walden M., Schafer S., Genz S., and Forssmann W.-G. Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 378 (2004) 879-883
13. Anderson L., and Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5 (2006) 573-588
14. Ackermann B.L., and Berna M.J. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev. Proteomics 4 (2007) 175-186
15. Weinzierl A.O., and Stefanovic S. LC-MS-based protein and peptide quantification using stable isotope labels: from ICAT in general to differential N-terminal coding (dNIC) in particular. Biotechnol. Genet. Eng. Rev. 23 (2006) 21-39
16. Barnidge D.R., Hall G.D., Stocker J.L., and Muddiman D.C. Evaluation of a cleavable stable isotope labeled synthetic peptide for absolute protein quantification using LC-MS/MS. J. Protein Res. 3 (2004) 658-661
17. Liu T., Qian W.-J., Strittmatter E.F., Camp II D.G., Gordon G.A., Thrall B.D., and Smith R.D. High-throughput comparative proteome analysis using a quantitative cysteinyl-peptide enrichment technology. Anal. Chem. 76 (2004) 5345-5353
18. Govorukhina N.I., Reijmers T.H., Nyangoma S.O., van der Zee A.G.J., Jansen R.C., and Bischoff R. Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. J. Chromatogr. A 1120 (2006) 142-150
19. Rajinder S., McEwan M., Lamb J.H., Santella R.M., and Farmer P.B. An improved liquid chromatography/tandem mass spectrometry method for the determination of 8-oxo-7,8-dihydro-2(-deoxyguanosine in DNA samples using immunoaffinity column purification. Rapid Commun. Mass Spectrom. 17 (2003) 126-134
20. Li W., and Cohen L. Quantitation of endogenous analytes in biofluid without a true blank matrix. Anal. Chem. 75 (2003) 5854-5859
21. Jemal M., Schuster A., and Whigan D.B. Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard. Rapid Commun. Mass Spectrom. 17 (2003) 1723-1734
22. Pickering E., Szekely-Klepser G., Nemirovskiy O., Li W., Brown R., Sunyer T., and Hellio Le Graverand M.-P. Urinary type II collagen neo-epitope (uTIINE): a marker of osteoarthritis activity [abstract]. Osteoarthritis Cartilage 12 Suppl. B (2004) S93
23. Hellio Le Graverand M.-P., Brandt K.D., Mazzuza S.A., Katz B.P., Buck R., Lane K.A., Pickering E., Nemirovskiy O.V., Sunyer T., and Welsch D.J. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 14 (2006) 1189-1195